Paradigm Capital Management Inc. NY Grows Position in AngioDynamics, Inc. $ANGO

Paradigm Capital Management Inc. NY grew its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 5.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 718,200 shares of the medical instruments supplier’s stock after purchasing an additional 40,000 shares during the period. Paradigm Capital Management Inc. NY owned approximately 1.74% of AngioDynamics worth $8,166,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Farther Finance Advisors LLC raised its holdings in AngioDynamics by 146.4% in the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 1,199 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in AngioDynamics during the fourth quarter worth approximately $27,000. State of Wyoming acquired a new stake in shares of AngioDynamics in the second quarter worth $31,000. Russell Investments Group Ltd. raised its stake in shares of AngioDynamics by 329.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 3,213 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in shares of AngioDynamics by 359.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 4,268 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ANGO. HC Wainwright upped their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Freedom Capital raised AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. Canaccord Genuity Group boosted their price objective on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Zacks Research downgraded AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, AngioDynamics presently has a consensus rating of “Hold” and an average price target of $19.50.

AngioDynamics Trading Up 1.1%

NASDAQ ANGO opened at $13.59 on Friday. The stock has a market cap of $561.67 million, a P/E ratio of -15.62 and a beta of 0.34. The company’s fifty day simple moving average is $12.53 and its 200-day simple moving average is $11.39. AngioDynamics, Inc. has a 52 week low of $8.36 and a 52 week high of $15.19.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $86.61 million during the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, research analysts expect that AngioDynamics, Inc. will post -0.27 EPS for the current fiscal year.

AngioDynamics Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.